Her-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer

Seminars in Oncology

Volumn 27, Issue 6 SUPPL. 11, 2000, Pages 53-63

  Agus, D B ^a   Bunn P A , Jr ^a   Franklin, W ^a   Garcia, M ^a   Ozols, R F ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; TRASTUZUMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG POTENTIATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; META ANALYSIS; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENES, ERBB-2; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS, HORMONE-DEPENDENT; OVARIAN NEOPLASMS; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 0034473197     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Molecular abnormalities in lung cancer
2. Amplification and expression of protooncogenes in human small cell lung cancer cell lines
3. Oncogene overexpression in non-small cell lung tissue: Prevalence and clinicopathological significance
4. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody
5. Activity of anti-erbB-2 recombinant toxin OLX-209 on lung cancer cell lines in the absence of erbB-2 gene amplification
6. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin
7. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung
8. Comparison of features of human lung cancer cell lines and their corresponding tumors
9. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer
10. Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines
11. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines
12. Abnormalities of protooncogenes in non-small cell lung cancer. Correlations with tumor type and clinical characteristics
13. P185neu in human lung adenocarcinomas predicts shortened expression survival
14. Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients
15. Localized adenocarcinoma of the lung: Oncogene expression of erbB-2 and p53 in 150 patients
16. Gender comparisons in human lung cancer: Analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression
17. Non-small cell lung cancer: C-erbB-2 overexpression correlates with low angiogenesis and poor prognosis
18. Clinicopathologic analysis of k-ras, p53, and ERBB-2 gene alterations in pulmonary adenocarcinoma
19. Oncoprotein (c-myc, c-cerbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations
20. Amplification of protooncogenes in surgical specimens of human lung carcinomas
21. Immunocytochemical markers in stage I lung cancer: Relevance to prognosis
22. Correlation between molecular genetic analyses and immunohistochemical evaluation of the epidermal growth factor receptor and p185HER2
23. Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients: Clinical implications
24. The interactive effect of Ras, HER2, p53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients
25. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
26. Analysts of combined drug effects: A new look at a very old problem
27. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
28. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
29. Expression of HER-2/neu oncoprotein, DNA-ploidy and S-phase fraction in advanced ovarian cancer
30. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis
31. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy
32. C-erbB2 gene amplification and protein expression in ovarian epithelial tumors: Evaluation of their respective prognostic significance by multivariate analysis
33. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas
34. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma
35. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
36. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines
37. Update of the National Comprehensive Cancer Network ovarian cancer practice guidelines
38. A phase II evaluation of anti-HER-2/neu antibody (NSC #688097) (IND #6667) in recurrent or refractory ovarian or primary peritoneal carcinoma
39. Overexpression of HER-2/neu in human prostate cancer and benign hyperplasia
40. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization
41. Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer
42. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma
43. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma
44. Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines
45. Expression of epidermal growth factor receptor and ERBB2 (HER-2/ neu) oncoprotein in prostatic carcinomas
46. Response of prostate cancer to anti-HER-2/neu antibody in androgen-dependent and independent human xenograft models
47. CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar
48. CWR22: Androgen-dependent xenograft model derived from a primary human prostatic carcinoma
49. Workgroup 2: Human xenograft models of prostate cancer
50. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase